Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

April 30, 2029

Conditions

Lung CancerCarcinoma, Squamous Cell

Interventions

DRUG

Osimertinib

Patients with resectable stage II-IIIB EGFR-mutated lung squamous cell carcinoma will receive Osimertinib ( 80mg/d, ≥9 weeks).

Trial Locations (1)

RECRUITING

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors

lead

The First Affiliated Hospital of Guangzhou Medical University

OTHER